[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shandong University of Traditional Chinese Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":75},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100565639","phase-3-progesterone-modified-natural-cycle-for-fet-100565639",false,"NCT06644794","Progesterone-modified Natural Cycle for FET","Comparison of Progesterone-modified Natural Cycle and Hormone Replacement Therapy Cycle for Endometrial Preparation in Single Frozen Blastocyst Transfer","COMPROSET","Inclusion Criteria:\n\n* Patients aged 21 to 44 years undergoing FBT\n* Body mass index (BMI) 18-35 kg\u002Fm2\n* Having regular ovulatory cycles\n\nExclusion Criteria:\n\n* Untreated uterine adhesions\n* Medical contraindications to estrogen and progesterone therapy\n* Illnesses contraindicating assisted reproductive technology or pregnancy\n* History of recurrent implantation failures (\\> 2 embryo transfer failures)","FEMALE","21 Years","44 Years",{"count":21,"type":22},336,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Hormone replacement therapy (HRT) cycles, despite the ease of synchronizing embryo thawing and embryo transfer timing, increase the risk of pregnancies and obstetric complications compared to natural cycles (NC). By ensuring the presence of the corpus luteum while reducing the number of monitoring sessions, the progesterone modified natural cycle (P4mNC) offers more convenience for the patient than the normal NC. This study is designed to compare the effects of P4mNC and HRT cycles on FET outcomes.",[28],"Infertility, Female",[30,31,32],"Progesterone-modified natural cycle","Hormone replacement therapy","Frozen-thawed embryo transfer","RECRUITING","2026-04-23",{"date":36,"type":37},"2026-04-29","ACTUAL",{"date":39,"type":37},"2025-03-05",{"date":41,"type":22},"2028-12-01",{"name":43,"class":44},"Shandong University of Traditional Chinese Medicine","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":45},"100429483","phase-4-efficacy-and-safety-of-gushen-antai-pill-on-ongoing-pregnancy-rate-in-women-with-normal-ovarian-reserve-undergoing-ivf-et-100429483","NCT04872660","Efficacy and Safety of Gushen Antai Pill on Ongoing Pregnancy Rate in Women With Normal Ovarian Reserve Undergoing IVF-ET","Efficacy and Safety of Gushen Antai Pill on Ongoing Pregnancy Rate in Women With Normal Ovarian Reserve Undergoing in Vitro Fertilization Embryo Transfer: A Prospective, Multicentre, Randomised, Double-blind, Placebo-controlled Trial","GSATP-FreET","Inclusion Criteria:\n\n* Patients with normal ovarian function reserve (5 ≤ AFC ≤ 15, 1.2 ng\u002Fml ≤ AMH ≤ 3.5 ng\u002Fml).\n* Patients with regular menstrual cycle (21-35 days) and normal ovulation.\n* Initial IVF \u002F ICSI treatment.\n* At least one embryo or blastocyst available for transfer.\n\nExclusion Criteria:\n\n* Age ≥ 43 years old.\n* Body mass index (BMI) ≥ 28 Kg\u002Fm2.\n* \"Freeze-all\" strategy.\n* Those using the natural cycle or mild stimulation for IVF\u002FICSI treatment.\n* Individuals with severe hyperstimulation ovarian syndrome during controlled ovarian stimulation.\n* Acceptors of donated oocytes or performed either In vitro Maturation (IVM) or blastocyst biopsy for Preimplantation Genetic Diagnosis (PGD) or Preimplantation Genetic Testing for Aneuploidies (PGT-A).\n* History of two or more previous consecutive spontaneous abortions.\n* History of two or more previous IVF-ET failures.\n* Karyotype abnormalities.\n* Polycystic ovary syndrome.\n* Presence of a non-surgically treated hydrosalpinx, uterine cavity fluid or endometrial polyp and an ovarian endometriosis cyst requiring surgery, during ovarian stimulation.\n* Congenital or acquired abnormalities of uterine anatomy.\n* Combined contraindications to assisted reproductive technology or pregnancy, such as uncontrolled abnormalities of liver and kidney function, diabetes mellitus (glycosylated haemoglobin ≤7%, fasting blood glucose \\\u003C10 mmol\u002FL ), hypertension, thyroid disease, symptomatic heart disease, moderate to severe anaemia, history of malignancy or thromboembolism or propensity to thrombosis, severe psychiatric disorder, acute infections of the genitourinary system, sexually transmitted diseases, serious adverse habits such as drug abuse, exposure to teratogenic amounts of radiation, toxins, or drugs (such as prednisone or other hormones, adrenaline, antibiotics, or hypertension, cardiovascular, or antiviral medications) during the active procedure period , and uterine factor infertility or physical illness which prevents the ability to bear a pregnancy.","42 Years",{"count":56,"type":22},800,[58],"PHASE4","The purpose of this study is to investigate whether oral Gushen Antai pills supplementation for luteal phase support will improve ongoing pregnancy rate in women with normal ovarian reserve in fresh embryo transfer cycles.",[28],[62,63,64,65,66],"Traditional Chinese Medicine","In vitro fertilization-embryo transfer","Gushen Antai Pill","Normal ovarian reserve","Ongoing pregnancy rate","2026-03-06",{"date":69,"type":37},"2026-03-10",{"date":71,"type":37},"2021-06-15",{"date":73,"type":22},"2026-12-30",{"name":43,"class":44},""]